Health
Comparison of oral vs intravenous etoposide in the management of small‐cell lung cancer: A real‐world, population‐based study – MD Linx
MDLinx original journal summary on Lung Cancer, Pulmonology from The Clinical Respiratory Journal
For firstline treatment in smallcell lung cancer (SCLC), researchers assessed whether PO vs IV etoposide is useful in combination with a platinum agent (cisplatin/carboplatin) in this study including 2,066 patients with SCLC. Based on stage, patients were divided as limited disease and extensive disease. Route of etoposide administration, dose reductions and vital status was evaluated in chemotherapy naïve patients receiving one cycle of combination chemotherapy. Findings revealed similar overal…
-
General18 hours agoGymnastics club in Berwick shuts down following child safety complaint
-
Noosa News21 hours agoSanta drops in for carols
-
General23 hours agoCritically endangered orchid thrives as NSW Mid North Coast cemetery provides habitat refuge
-
Business23 hours agoThe best Australian stock you’ve never heard of